Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,666
archived clinical trials in
Hospital

IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Ucsd Medical Center; Kidney Transplantation
mi
from
San Diego, CA
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Ucsd Medical Center; Kidney Transplantation
mi
from
San Diego, CA
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
California Pacific Medical Center
mi
from
San Francisco, CA
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Uni of California San Francisco; Transplant Services
mi
from
San Francisco, CA
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Uni of California San Francisco; Transplant Services
mi
from
San Francisco, CA
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Lifelink Healthcare Inst.
mi
from
Tampa, FL
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Lifelink Healthcare Inst.
mi
from
Tampa, FL
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Rush-Presbyterian St. Luke'S Medical Center; Rush Uni Renal Transplant Program
mi
from
Chicago, IL
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Rush-Presbyterian St. Luke'S Medical Center; Rush Uni Renal Transplant Program
mi
from
Chicago, IL
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Indiana Uni Medical Center; Surgery & Microbiology/Immunology
mi
from
Indianapolis, IN
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Indiana Uni Medical Center; Surgery & Microbiology/Immunology
mi
from
Indianapolis, IN
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
New England Medical Center; Division of Transplant Surgery
mi
from
Boston, MA
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
New England Medical Center; Division of Transplant Surgery
mi
from
Boston, MA
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Uni of Michigan Medical Center
mi
from
Ann Arbor, MI
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Uni of Michigan Medical Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Uni of Minnesota Medical Center; Dept of Surgery
mi
from
Minneapolis, MN
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Uni of Minnesota Medical Center; Dept of Surgery
mi
from
Minneapolis, MN
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Hackensack University Medical Center
mi
from
Hackensack, NJ
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
St. Barnabas Medical Center
mi
from
Livingston, NJ
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
St. Barnabas Medical Center
mi
from
Livingston, NJ
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Robert Wood Johnson Uni Hospital; Anesthesia
mi
from
New Brunswick, NJ
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Robert Wood Johnson Uni Hospital; Anesthesia
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Wake Forest Uni School of Medicine; Section on Infectious Diseases
mi
from
Winston-Salem, NC
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Wake Forest Uni School of Medicine; Section on Infectious Diseases
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Oregon Health Sciences Uni ; Division of Nephrology
mi
from
Portland, OR
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Oregon Health Sciences Uni ; Division of Nephrology
mi
from
Portland, OR
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Hahnemann Uni Hospital; Division of Transplant/Dept. of Surgery
mi
from
Philadelphia, PA
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Hahnemann Uni Hospital; Division of Transplant/Dept. of Surgery
mi
from
Philadelphia, PA
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Uni of Pennslyvania Medical Center
mi
from
Philadelphia, PA
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Uni of Pennslyvania Medical Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Vanderbilt Uni ; Divison of Nephrology
mi
from
Nashville, TN
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Vanderbilt Uni ; Divison of Nephrology
mi
from
Nashville, TN
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Texas Transplant Inst.
mi
from
San Antonio, TX
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Texas Transplant Inst.
mi
from
San Antonio, TX
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Uni of Texas Health Science Center At San Antonio; Organ Transplant Program
mi
from
San Antonio, TX
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Uni of Texas Health Science Center At San Antonio; Organ Transplant Program
mi
from
San Antonio, TX
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Uni of Washington Medical Center; Division of Allergy & Infectious Diseases
mi
from
Seattle, WA
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Uni of Washington Medical Center; Division of Allergy & Infectious Diseases
mi
from
Seattle, WA
Click here to add this to my saved trials
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated:  2/28/2018
Royal Prince Alfred Hospital; Renal Transplant Unit
mi
from
Camperdown,
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients
Status: Enrolling
Updated: 2/28/2018
Royal Prince Alfred Hospital; Renal Transplant Unit
mi
from
Camperdown,
Click here to add this to my saved trials
Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation
A Prospective Single Center Randomized Trial of Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation.
Status: Enrolling
Updated:  3/2/2018
Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA
mi
from
Los Angeles, CA
Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation
A Prospective Single Center Randomized Trial of Intraoperative Versus Postoperative Thymoglobulin in Lung Transplantation.
Status: Enrolling
Updated: 3/2/2018
Departments of Pulmonary and Critical Care, Cardiothoracic Surgery and Infectious Diseases at David Geffen School of Medicine at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
University of Colorado
mi
from
Aurora, CO
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
University of Florida Gainesville
mi
from
Gainesville, FL
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
University of Florida Gainesville
mi
from
Gainesville, FL
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
Tampa General Hospital
mi
from
Tampa, FL
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
Tampa General Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
University of Chicago
mi
from
Chicago, IL
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
Indiana University Health
mi
from
Indianapolis, IN
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
Indiana University Health
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
University of Michigan
mi
from
Ann Arbor, MI
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
Henry Ford
mi
from
Detroit, MI
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
Henry Ford
mi
from
Detroit, MI
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
Columbia University Medical Centre
mi
from
New York, NY
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
Columbia University Medical Centre
mi
from
New York, NY
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
Duke University
mi
from
Durham, NC
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
Ohio State University
mi
from
Columbus, OH
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
University of Texas Southwestern
mi
from
Dallas, TX
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
University of Washington Medical Center
mi
from
Seattle, WA
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
University of Maryland
mi
from
Baltimore, MD
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated:  3/5/2018
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs
Status: Enrolling
Updated: 3/5/2018
Barnes Jewish Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Improving Gait Performance in Individuals With Spinal Cord Injuries: an Intervention Using Robotic Exoskeletons
Improving Gait Performance in Individuals With Spinal Cord Injuries: an Intervention Using Robotic Exoskeletons
Status: Enrolling
Updated:  3/5/2018
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Improving Gait Performance in Individuals With Spinal Cord Injuries: an Intervention Using Robotic Exoskeletons
Improving Gait Performance in Individuals With Spinal Cord Injuries: an Intervention Using Robotic Exoskeletons
Status: Enrolling
Updated: 3/5/2018
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock
Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock
Status: Enrolling
Updated:  3/6/2018
Cleveland Clinic
mi
from
Cleveland, OH
Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock
Hemodynamic and Inflammatory Effects of Abrupt Versus Tapered Corticosteroid Discontinuation in Septic Shock
Status: Enrolling
Updated: 3/6/2018
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery
Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery: A Prospective Randomized, Double-blind, Placebo-controlled Trial
Status: Enrolling
Updated:  3/6/2018
University of Wisconsin School of Medicine and Public Health
mi
from
Madison, WI
Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery
Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery: A Prospective Randomized, Double-blind, Placebo-controlled Trial
Status: Enrolling
Updated: 3/6/2018
University of Wisconsin School of Medicine and Public Health
mi
from
Madison, WI
Click here to add this to my saved trials
The SOMNUS Study: Sedative Optimization Via Monitoring Neurological Status
A Randomized Control Trial Using the BIS Monitor to Avoid Over Sedation and Prolonged Neuropsychological Deficits in Mechanically Ventilated ICU Patients
Status: Enrolling
Updated:  3/6/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
The SOMNUS Study: Sedative Optimization Via Monitoring Neurological Status
A Randomized Control Trial Using the BIS Monitor to Avoid Over Sedation and Prolonged Neuropsychological Deficits in Mechanically Ventilated ICU Patients
Status: Enrolling
Updated: 3/6/2018
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Neural Bases of Cognitive Rehabilitation for Brain Injury
Neural Bases of Cognitive Rehabilitation for Brain Injury
Status: Enrolling
Updated:  3/9/2018
Martinez Outpatient Clinic and Community Living Center, Martinez, CA
mi
from
Martinez, CA
Neural Bases of Cognitive Rehabilitation for Brain Injury
Neural Bases of Cognitive Rehabilitation for Brain Injury
Status: Enrolling
Updated: 3/9/2018
Martinez Outpatient Clinic and Community Living Center, Martinez, CA
mi
from
Martinez, CA
Click here to add this to my saved trials
Prospective Trial of Alerting to Extended Hypotensive Exposures on Long-Term Outcome After Surgery
Prospective, Randomized Trial of Alerting to Extended Hypotensive Exposures on Long-Term Outcome Following Adult Non-Cardiac Surgical Procedures: The SLUScore™ Trial
Status: Enrolling
Updated:  3/12/2018
Saint Louis University Hospital
mi
from
Saint Louis, MO
Prospective Trial of Alerting to Extended Hypotensive Exposures on Long-Term Outcome After Surgery
Prospective, Randomized Trial of Alerting to Extended Hypotensive Exposures on Long-Term Outcome Following Adult Non-Cardiac Surgical Procedures: The SLUScore™ Trial
Status: Enrolling
Updated: 3/12/2018
Saint Louis University Hospital
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Zoledronic Acid Administration in Acute Spinal Cord Injury
The Efficacy of Zoledronic Acid in the Prevention of Bone Loss in Acute Spinal Cord Injury
Status: Enrolling
Updated:  3/12/2018
Kessler Institute for Rehabilitation
mi
from
West Orange, NJ
Zoledronic Acid Administration in Acute Spinal Cord Injury
The Efficacy of Zoledronic Acid in the Prevention of Bone Loss in Acute Spinal Cord Injury
Status: Enrolling
Updated: 3/12/2018
Kessler Institute for Rehabilitation
mi
from
West Orange, NJ
Click here to add this to my saved trials
Impact of V.A.C. Veraflo Therapy in Wounds Requiring Debridement Within an Orthopedic Practice
Impact of V.A.C. Veraflo Therapy in Wounds Requiring Debridement Within an Orthopedic Practice
Status: Enrolling
Updated:  3/13/2018
Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, LifeBridge Health
mi
from
Baltimore, MD
Impact of V.A.C. Veraflo Therapy in Wounds Requiring Debridement Within an Orthopedic Practice
Impact of V.A.C. Veraflo Therapy in Wounds Requiring Debridement Within an Orthopedic Practice
Status: Enrolling
Updated: 3/13/2018
Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, LifeBridge Health
mi
from
Baltimore, MD
Click here to add this to my saved trials
Utility of an Animated Bowel Biofeedback Training Routine to Improve Bowel Function in Individuals With SCI
Bowel Biofeedback Training to Improve Bowel Function in Individuals With SCI
Status: Enrolling
Updated:  3/13/2018
James J. Peters VA Medical Center, Bronx, NY
mi
from
Bronx, NY
Utility of an Animated Bowel Biofeedback Training Routine to Improve Bowel Function in Individuals With SCI
Bowel Biofeedback Training to Improve Bowel Function in Individuals With SCI
Status: Enrolling
Updated: 3/13/2018
James J. Peters VA Medical Center, Bronx, NY
mi
from
Bronx, NY
Click here to add this to my saved trials
Effectiveness of CelluTome Epidermal Harvesting System in Autologous Skin Grafting of Chronic Wound Patients
Effectiveness of CelluTome Epidermal Harvesting System in Autologous Skin Grafting of Chronic Wound Patients
Status: Enrolling
Updated:  3/13/2018
Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, LifeBridge Health
mi
from
Baltimore, MD
Effectiveness of CelluTome Epidermal Harvesting System in Autologous Skin Grafting of Chronic Wound Patients
Effectiveness of CelluTome Epidermal Harvesting System in Autologous Skin Grafting of Chronic Wound Patients
Status: Enrolling
Updated: 3/13/2018
Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, LifeBridge Health
mi
from
Baltimore, MD
Click here to add this to my saved trials